Tumor cells expressing anti-CD137 scFv induce a tumor-destructive environment

Cancer Research

Volumn 67, Issue 5, 2007, Pages 2339-2344

  Yang, Yi ^a   Yang, Shilin ^a,b   Ye, Zhengmao ^a,c   Jaffar, Jade ^a   Zhou, Yifeng ^a   Cutter, Erin ^a   Lieber, Andre ^a   Hellström, Ingegerd ^a   Hellström, Karl Erik ^a,d  

^a UNIVERSITY OF WASHINGTON   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CD137 ANTIBODY; GAMMA INTERFERON; MONOCLONAL ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ T LYMPHOCYTE; CELL TRANSPLANTATION; CONTROLLED STUDY; FEMALE; LYMPH NODE; MELANOMA B16; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SPLEEN; TUMOR CELL;

ANIMALS; ANTIGENS, CD137; FEMALE; IMMUNITY, CELLULAR; IMMUNOGLOBULIN FRAGMENTS; IMMUNOTHERAPY; LYMPH NODES; LYMPHOKINES; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C3H; NEOPLASM TRANSPLANTATION; RECOMBINANT FUSION PROTEINS; SPLEEN; TUMOR CELLS, CULTURED;

EID: 33947232721     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-3593     Document Type: Article

References (32)

1. Hellstrom KE, Hellstrom I. Novel approaches to therapeutic cancer vaccines. Expert Rev Vaccines 2003; 2:517-32.
2. Turk MJ, Guevara-Patino JA, Rizzuto GA, Engelhorn ME, Houghton AN. Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J Exp Med 2004;200:771-82.
3. Seliger B, Maeurer MJ, Ferrone S. Antigen-processing machinery breakdown and tumor growth. Immunol Today 2000;21:455-64.
4. Ye Z, Hellstrom I, Hayden-Ledbetter M, Dahlin A, Ledbetter JA, Hellstrom KE. Gene therapy for cancer using single-chain Fv fragments specific for 4-1BB. Nat Med 2002;8:343-8.
5. Fidler IJ, Hart IR. Biological and experimental consequences of the clonal composition of solid tumors. Cancer Res 1981;41:3266-7.
6. Ward PI, Koeppen H, Hurteau T, Schreiber H. Tumor antigens defined by cloned immunological probes are highly polymorphic and are not detected on autologous normal cells. J Exp Med 1989;170:217-32.
7. Feltkamp MCW, Smits HL, Vierboom MPM, et al. Vaccination with cytotoxic T lymphocyte epitoe-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 1993;23:2242-9.
8. Fidler IJ, Gersten DM, Budmen MB. Characterization in vivo and in vitro of tumor cells selected for resistance to syngeneic lymphocyte-mediated cytotoxicity. Cancer Res 1976;36:3160-5.
9. Di Paolo NC, Tuve S, Ni S, Hellstrom KE, Hellstrom I, Lieber A. Effect of adenovirus-mediated heat shock protein expression and oncolysis in combination with low-dose cyclophosphamide treatment on antitumor immune responses. Cancer Res 2006;66:960-9.
10. + T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J Exp Med 1997; 186:47-55.
11. Winberg G, Grosmaire LS, Klussman K, et al. Surface expression of CD28 single chain Fv for costimulation by tumor cells. Immunol Rev 1996;153:209-23.
12. Carlson CA, Shayakhmetov DM, Lieber A. An adenoviral expressionsystem for AAV Rep 78 using homologous recombination. Mol Ther 2002;6:91-8.
13. Carlson CA, Steinwaerder DS, Stecher H, Shayakhmetov DM, Lieber A. Rearrangements in adenovirual genomes mediated by inverted repeats. Methods Enzymol 2002;346: 277-92.
14. Chen L, Ashe S, Brady WA, et al. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 1992;71: 1093-102.
15. Chapoval AI, Nelson H, Thibault C. Anti-CD3 x antitumor F(ab′)2 bifunctional antibody activates and retargets tumor-infiltrating lymphocytes. J Immunol 1995;155:1296-303.
16. + T regulatory cells. Nat Immunol 2003;4:337-42.
17. Fidler IJ, Poste G. Macrophage-mediated destruction of malignant utmor cells and new strategies for the therapy of metastatic disease. Springer Semin Immunopathol 1982;5:161-74.
18. + T cell clones specific for the human p97 melanoma-associated antigen can eradicate pulmonary metastases from a murine tumor expressing the p97 antigen. J Immunol 1991;146:3235-41.
19. Hurtado JC, Kim SH, Pollok KE, Lee ZH, Kwon BS. Potential role of 4-1BB in T cell activation. Comparison with the costimulatory molecule CD28. J Immunol 1995; 155:3360-7.
20. Melero I, Johnston JV, Shufford WW, Mittler RS, Chen L. NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies. Cell Immunol 1998;190:167-72.
21. Langstein J, Schwartz H. Identification of CD137 as a potent monocyte survival factor. J Leukoc Biol 1999;65: 829-33.
22. Futagawa T, Akiba H, Kodama T, et al. Expression and function of 4-1BB and 4-1BB ligand on murine dendritic cels. Int Immunol 2002;14:275-86.
23. Melero I, Shuford WW, Newby SA, et al. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med 1997;3:682-5.
24. Zhang H, Knutson L, Hellstrom KE, Disis ML, Hellstrom I. Antitumor efficacy of CD137 ligation is maximized by the use of a CD137 single-chain Fv-expressing whole-cell tumor vaccine compared with CD137-specific monoclonal antibody infusion. Mol Cancer Ther 2006;5:149-55.
25. Melero I, Bach N, Hellstrom KE, Aruffo A, Mittler RS, Chen L. Amplification of tumor immunity by gene transfer of the co-stimulatory 4-1BB ligand: synergy with the CD28 co-stimulatory pathway. Eur J Immunol 1998; 28:1116-21.
26. Schwarz H. Biological activities of reverse signal transduction through CD137 ligand. J Leukoc Biol 2005; 77:281-6.
27. Bielas JH, Loeb KR, Rubin BP, True LD, Loeb LA. Human cancers express a mutator phenotype. Proc Natl Acad Sci U S A 2006;103:18238-42.
28. Koprowski H, Herlyn D, Lubeck M, DeFreitas E, Sears HF. Human anti-idiotype antibodies in cancer patients: is the modulation of the immune response beneficial for the patient? Proc Natl Acad Sci U S A 1984; 81:216-9.
29. Sears HF, Herlyn D, Steplewski Z, Koprowski H. Initial trial use of murine monoclonal antibodies as immunotherapeutic agents for gastointestinal adenocarcinoma. Hybridoma 1986;5:109-15.
30. Pai LH, Wittes R, Setser A, Willingham MC, Pastan I. treatment of advanced solid tumors with immunotoxin LMB-1: an antibody linked to Pseudomonas exotoxin. Nat Med 1996;2:350-3.
31. Segal DM, Weiner GJ, Weiner LM. Introduction: bispecific antibodies. J Immunol Methods 2001;248: 1-6.
32. Gaggar A, Shayakhmetov DM, Lieber A. CD46 is a cellular receptor for group B adenoviruses. Nat Med 2003;9:1408-12.